Scholar Rock Outlines 2025 Financials, Strategic Advances, and Future Outlook
Scholar Rock Holding Corp. (SRRK) reported its financial results and operational highlights for the year 2025, showcasing progress in its pipeline and strategic positioning. The company, focused on neuromuscular diseases, experienced a net loss of $377.9 million, compared to a net loss of $246.3 million in 2024. Research and development expenses totaled $208.4 million, up from $184.6 million in the previous year, driven by increased investment in its lead program, apitegromab, and other early development candidates. General and administrative expenses also saw a significant increase, reaching $176.2 million compared to $67.5 million in 2024, primarily due to investments in commercial infrastructure and personnel.
Despite the losses, Scholar Rock highlighted key operational achievements, including the submission of a Biologics License Application (BLA) to the FDA and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for apitegromab in spinal muscular atrophy (SMA). The company received Priority Review designation from the FDA for the BLA. However, the company received a Complete Response Letter (CRL) from the FDA related to observations identified during a routine general site inspection of a third-party fill-finish facility. The company completed a constructive in-person Type A meeting with the FDA in November 2025, and plans to resubmit the apitegromab BLA at such time after the facility resolves the cGMP deficiencies identified in the CRL. Scholar Rock also transformed its leadership team, appointing David Hallal as Chief Executive Officer and other key executives to strengthen its commercial capabilities.
Key operational developments included initiating dosing in the Phase 2 OPAL study evaluating apitegromab in infants and toddlers under 2 years of age with SMA, advancing preclinical development of apitegromab for facioscapulohumeral muscular dystrophy (FSHD), completing a Phase 1 study of subcutaneous apitegromab in healthy volunteers, and initiating dosing in a Phase 1 study evaluating SRK-439 in healthy volunteers. The company also progressed its strategic plan to build a robust pipeline of therapies for the treatment of people living with rare, severe, and debilitating neuromuscular diseases. Employee headcount stood at 289 as of February 24, 2026, with a focus on expanding commercial and field teams in the U.S. and Europe.
Looking ahead, Scholar Rock anticipates 2026 to be a transformational year, with potential regulatory approvals for apitegromab in the U.S. and Europe. The company plans to commercialize apitegromab for children and adults living with SMA, expand apitegromab's impact to infants and toddlers with SMA and to additional rare, severe, and debilitating neuromuscular diseases, and advance its leading anti-myostatin pipeline. The company believes its existing cash, cash equivalents, and marketable securities of $367.6 million as of December 31, 2025, will be sufficient to fund operating expenses and capital expenditure requirements into 2027. However, additional capital will be required to complete clinical development and commercialization of its programs.
About Scholar Rock Holding Corp
Scholar Rock is a biopharmaceutical company specializing in the discovery and development of monoclonal antibodies targeting latent growth factors, primarily within the TGF-β superfamily. Its proprietary platform enables selective inhibition of growth factor activation in disease microenvironments, aiming to treat neuromuscular disorders, cancer, fibrosis, and cardiometabolic diseases. The company’s lead candidate, apitegromab, targets muscle atrophy in SMA, while others focus on cancer and fibrosis, emphasizing precision medicine and innovative therapeutic approaches.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.